{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T13:15:46Z","timestamp":1788959746515,"version":"build-2803163510"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,11,6]]},"DOI":"10.7759\/cureus.73150","type":"journal-article","created":{"date-parts":[[2024,11,6]],"date-time":"2024-11-06T13:17:41Z","timestamp":1730899061000},"source":"Crossref","is-referenced-by-count":11,"title":["Gut Microbiome and Its Role in Parkinson's Disease"],"prefix":"10.7759","author":[{"given":"Suchith B","family":"Suresh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aparna","family":"Malireddi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahlet","family":"Abera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khutaija","family":"Noor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehwish","family":"Ansar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sruthi","family":"Boddeti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tuheen Sankar","family":"Nath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","unstructured":"Parkinson disease. (2023). Accessed. August 1, 2024: http:\/\/www.who.int\/news-room\/fact-sheets\/detail\/parkinson-disease."},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1002\/brb3.3130","article-title":"Parkinson's disease: are gut microbes involved?","volume":"13","author":"Omotosho AO","year":"2023","unstructured":"Omotosho AO, Tajudeen YA, Oladipo HJ, et al.. Parkinson's disease: are gut microbes involved?. Brain Behav. 2023, 13:e3130. 10.1002\/brb3.3130","journal-title":"Brain Behav"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2021.615075","article-title":"Review: the role of intestinal dysbiosis in Parkinson's disease","volume":"11","author":"Huang Y","year":"2021","unstructured":"Huang Y, Liao J, Liu X, Zhong Y, Cai X, Long L. Review: the role of intestinal dysbiosis in Parkinson's disease. Front Cell Infect Microbiol. 2021, 11:615075. 10.3389\/fcimb.2021.615075","journal-title":"Front Cell Infect Microbiol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.3988\/jcn.2016.12.2.147","article-title":"Association between Parkinson's disease and Helicobacter pylori","volume":"12","author":"\u00c7amc\u0131 G","year":"2016","unstructured":"\u00c7amc\u0131 G, O\u011fuz S. Association between Parkinson's disease and Helicobacter pylori. J Clin Neurol. 2016, 12:147-50. 10.3988\/jcn.2016.12.2.147","journal-title":"J Clin Neurol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1002\/mds.26307","article-title":"Colonic bacterial composition in Parkinson's disease","volume":"30","author":"Keshavarzian A","year":"2015","unstructured":"Keshavarzian A, Green SJ, Engen PA, et al.. Colonic bacterial composition in Parkinson's disease. Mov Disord. 2015, 30:1351-60. 10.1002\/mds.26307","journal-title":"Mov Disord"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1080\/07853890.2021.1890330","article-title":"The gut-brain axis and Parkinson disease: clinical and pathogenetic relevance","volume":"53","author":"Menozzi E","year":"2021","unstructured":"Menozzi E, Macnaughtan J, Schapira AH. The gut-brain axis and Parkinson disease: clinical and pathogenetic relevance. Ann Med. 2021, 53:611-25. 10.1080\/07853890.2021.1890330","journal-title":"Ann Med"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1007\/s12223-022-00977-2","article-title":"Exploring the multifactorial aspects of gut microbiome in Parkinson's disease","volume":"67","author":"Pavan S","year":"2022","unstructured":"Pavan S, Prabhu AN, Prasad Gorthi S, et al.. Exploring the multifactorial aspects of gut microbiome in Parkinson's disease. Folia Microbiol (Praha). 2022, 67:693-706. 10.1007\/s12223-022-00977-2","journal-title":"Folia Microbiol (Praha)"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0028032","article-title":"Increased intestinal permeability correlates with sigmoid mucosa alpha-synuclein staining and endotoxin exposure markers in early Parkinson's disease","volume":"6","author":"Forsyth CB","year":"2011","unstructured":"Forsyth CB, Shannon KM, Kordower JH, et al.. Increased intestinal permeability correlates with sigmoid mucosa alpha-synuclein staining and endotoxin exposure markers in early Parkinson's disease. PLoS One. 2011, 6:e28032. 10.1371\/journal.pone.0028032","journal-title":"PLoS One"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2019.00369","article-title":"Alpha-synuclein pathology and the role of the microbiota in Parkinson's disease","volume":"13","author":"Fitzgerald E","year":"2019","unstructured":"Fitzgerald E, Murphy S, Martinson HA. Alpha-synuclein pathology and the role of the microbiota in Parkinson's disease. Front Neurosci. 2019, 13:369. 10.3389\/fnins.2019.00369","journal-title":"Front Neurosci"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.3892\/mmr.2021.12374","article-title":"Roles of \u03b1\u2011synuclein in gastrointestinal microbiome dysbiosis\u2011related Parkinson's disease progression (review)","volume":"24","author":"Lei Q","year":"2021","unstructured":"Lei Q, Wu T, Wu J, et al.. Roles of \u03b1\u2011synuclein in gastrointestinal microbiome dysbiosis\u2011related Parkinson's disease progression (review). Mol Med Rep. 2021, 24:734. 10.3892\/mmr.2021.12374","journal-title":"Mol Med Rep"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1186\/s13024-021-00427-6","article-title":"Relationships of gut microbiota, short-chain fatty acids, inflammation, and the gut barrier in Parkinson's disease","volume":"16","author":"Aho VT","year":"2021","unstructured":"Aho VT, Houser MC, Pereira PA, et al.. Relationships of gut microbiota, short-chain fatty acids, inflammation, and the gut barrier in Parkinson's disease. Mol Neurodegener. 2021, 16:6. 10.1186\/s13024-021-00427-6","journal-title":"Mol Neurodegener"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000037960","article-title":"Interplay of human gastrointestinal microbiota metabolites: short-chain fatty acids and their correlation with Parkinson's disease","volume":"103","author":"Liu J","year":"2024","unstructured":"Liu J, Chen Q, Su R. Interplay of human gastrointestinal microbiota metabolites: short-chain fatty acids and their correlation with Parkinson's disease. Medicine (Baltimore). 2024, 103:e37960. 10.1097\/MD.0000000000037960","journal-title":"Medicine (Baltimore)"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1111\/cns.13916","article-title":"New hope for Parkinson's disease treatment: targeting gut microbiota","volume":"28","author":"Fan HX","year":"2022","unstructured":"Fan HX, Sheng S, Zhang F. New hope for Parkinson's disease treatment: targeting gut microbiota. CNS Neurosci Ther. 2022, 28:1675-88. 10.1111\/cns.13916","journal-title":"CNS Neurosci Ther"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctim.2020.102507","article-title":"A systematic review and meta-analysis: the effects of probiotic supplementation on metabolic profile in patients with neurological disorders","volume":"53","author":"Tamtaji OR","year":"2020","unstructured":"Tamtaji OR, Milajerdi A, Reiner \u017d, et al.. A systematic review and meta-analysis: the effects of probiotic supplementation on metabolic profile in patients with neurological disorders. Complement Ther Med. 2020, 53:102507. 10.1016\/j.ctim.2020.102507","journal-title":"Complement Ther Med"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.937555","article-title":"Gut microbiota: a novel therapeutic target for Parkinson's disease","volume":"13","author":"Zhu M","year":"2022","unstructured":"Zhu M, Liu X, Ye Y, et al.. Gut microbiota: a novel therapeutic target for Parkinson's disease. Front Immunol. 2022, 13:937555. 10.3389\/fimmu.2022.937555","journal-title":"Front Immunol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.3390\/cells9020376","article-title":"Interventional influence of the intestinal microbiome through dietary intervention and bowel cleansing might improve motor symptoms in Parkinson's disease","volume":"9","author":"Hegelmaier T","year":"2020","unstructured":"Hegelmaier T, Lebbing M, Duscha A, et al.. Interventional influence of the intestinal microbiome through dietary intervention and bowel cleansing might improve motor symptoms in Parkinson's disease. Cells. 2020, 9:376. 10.3390\/cells9020376","journal-title":"Cells"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-024-01073-4","article-title":"The gut microbiota in Parkinson disease: interactions with drugs and potential for therapeutic applications","volume":"38","author":"Menozzi E","year":"2024","unstructured":"Menozzi E, Schapira AH. The gut microbiota in Parkinson disease: interactions with drugs and potential for therapeutic applications. CNS Drugs. 2024, 38:315-31. 10.1007\/s40263-024-01073-4","journal-title":"CNS Drugs"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1080\/19490976.2023.2284247","article-title":"Efficacy of fecal microbiota transplantation in patients with Parkinson's disease: clinical trial results from a randomized, placebo-controlled design","volume":"15","author":"Cheng Y","year":"2023","unstructured":"Cheng Y, Tan G, Zhu Q, et al.. Efficacy of fecal microbiota transplantation in patients with Parkinson's disease: clinical trial results from a randomized, placebo-controlled design. Gut Microbes. 2023, 15:2284247. 10.1080\/19490976.2023.2284247","journal-title":"Gut Microbes"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1177\/17590914211016217","article-title":"Gut microbiota and Parkinson's disease: implications for faecal microbiota transplantation therapy","volume":"13","author":"Kang Y","year":"2021","unstructured":"Kang Y, Kang X, Zhang H, Liu Q, Yang H, Fan W. Gut microbiota and Parkinson's disease: implications for faecal microbiota transplantation therapy. ASN Neuro. 2021, 13:17590914211016217. 10.1177\/17590914211016217","journal-title":"ASN Neuro"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.3390\/biom11030433","article-title":"New avenues for Parkinson's disease therapeutics: disease-modifying strategies based on the gut microbiota","volume":"11","author":"Lorente-Pic\u00f3n M","year":"2021","unstructured":"Lorente-Pic\u00f3n M, Laguna A. New avenues for Parkinson's disease therapeutics: disease-modifying strategies based on the gut microbiota. Biomolecules. 2021, 11:433. 10.3390\/biom11030433","journal-title":"Biomolecules"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2019.01245","article-title":"Diet in Parkinson's disease: critical role for the microbiome","volume":"10","author":"Jackson A","year":"2019","unstructured":"Jackson A, Forsyth CB, Shaikh M, Voigt RM, Engen PA, Ramirez V, Keshavarzian A. Diet in Parkinson's disease: critical role for the microbiome. Front Neurol. 2019, 10:1245. 10.3389\/fneur.2019.01245","journal-title":"Front Neurol"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1007\/s12035-021-02375-0","article-title":"Gut microbial metabolites in Parkinson's disease: implications of mitochondrial dysfunction in the pathogenesis and treatment","volume":"58","author":"Liang Y","year":"2021","unstructured":"Liang Y, Cui L, Gao J, Zhu M, Zhang Y, Zhang HL. Gut microbial metabolites in Parkinson's disease: implications of mitochondrial dysfunction in the pathogenesis and treatment. Mol Neurobiol. 2021, 58:3745-58. 10.1007\/s12035-021-02375-0","journal-title":"Mol Neurobiol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.1575","article-title":"Pharmacokinetics, safety, and tolerability of orally administered ursodeoxycholic acid in patients with Parkinson's disease-a pilot study","volume":"60","author":"Sathe AG","year":"2020","unstructured":"Sathe AG, Tuite P, Chen C, et al.. Pharmacokinetics, safety, and tolerability of orally administered ursodeoxycholic acid in patients with Parkinson's disease-a pilot study. J Clin Pharmacol. 2020, 60:744-50. 10.1002\/jcph.1575","journal-title":"J Clin Pharmacol"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2023.1265789","article-title":"Significant potential of melatonin therapy in Parkinson's disease - a meta-analysis of randomized controlled trials","volume":"14","author":"Iftikhar S","year":"2023","unstructured":"Iftikhar S, Sameer HM, Zainab. Significant potential of melatonin therapy in Parkinson's disease - a meta-analysis of randomized controlled trials. Front Neurol. 2023, 14:1265789. 10.3389\/fneur.2023.1265789","journal-title":"Front Neurol"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1038\/s41531-022-00327-6","article-title":"Probiotics synergized with conventional regimen in managing Parkinson's disease","volume":"8","author":"Sun H","year":"2022","unstructured":"Sun H, Zhao F, Liu Y, et al.. Probiotics synergized with conventional regimen in managing Parkinson's disease. NPJ Parkinsons Dis. 2022, 8:62. 10.1038\/s41531-022-00327-6","journal-title":"NPJ Parkinsons Dis"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1016\/j.gpb.2021.08.009","article-title":"Effects of resistant starch on symptoms, fecal markers, and gut microbiota in Parkinson's disease - the RESISTA-PD trial","volume":"20","author":"Becker A","year":"2022","unstructured":"Becker A, Schmartz GP, Gr\u00f6ger L, et al.. Effects of resistant starch on symptoms, fecal markers, and gut microbiota in Parkinson's disease - the RESISTA-PD trial. Genomics Proteomics Bioinformatics. 2022, 20:274-87. 10.1016\/j.gpb.2021.08.009","journal-title":"Genomics Proteomics Bioinformatics"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1007\/s11064-021-03411-0","article-title":"Fecal microbiota transplantation exerts a protective role in MPTP-induced Parkinson's disease via the TLR4\/PI3K\/AKT\/NF-\u03baB pathway stimulated by \u03b1-synuclein","volume":"46","author":"Zhong Z","year":"2021","unstructured":"Zhong Z, Chen W, Gao H, et al.. Fecal microbiota transplantation exerts a protective role in MPTP-induced Parkinson's disease via the TLR4\/PI3K\/AKT\/NF-\u03baB pathway stimulated by \u03b1-synuclein. Neurochem Res. 2021, 46:3050-8. 10.1007\/s11064-021-03411-0","journal-title":"Neurochem Res"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/304815-gut-microbiome-and-its-role-in-parkinsons-disease","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,6]],"date-time":"2024-11-06T13:17:43Z","timestamp":1730899063000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/304815-gut-microbiome-and-its-role-in-parkinsons-disease"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,6]]},"references-count":27,"URL":"https:\/\/doi.org\/10.7759\/cureus.73150","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11,6]]}}}